Skip to main content
. 2018 Jan 22;36(7):697–703. doi: 10.1200/JCO.2017.74.5083

Fig 3.

Fig 3.

Comparison of (A) progression-free survival (PFS) and (B) overall survival (OS) of patients with advanced-stage follicular lymphoma who received either six cycles of R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) or six cycles of CHOP-RIT (cyclophosphamide, doxorubicin, vincristine, and prednisone followed by consolidation with iodine-133–tositumomab radioimmunotherapy).